TWEAK/Fn14 axis-targeted therapeutics: Moving basic science discoveries to the clinic

Frontiers in Immunology

Volumn 4, Issue DEC, 2013, Pages

  Cheng, Emily ^a   Armstrong, Cheryl L ^a   Galisteo, Rebeca ^a   Winkles, Jeffrey A ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Clinical trial; Fn14; Inflammatory disease; TWEAK

Indexed keywords

EID: 84892180480     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00473     Document Type: Review

References (135)

1. Chicheportiche Y, Bourdon PR, Xu H, Hsu Y, Scott H, Hession C, et al. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem (1997) 272:32401-10. doi: 10.1074/jbc.272.51.32401
2. Wiley SR, Cassiano L, Lofton T, Davis-Smith T, Winkles JA, Lindner V, et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity (2001) 15:837-46. doi:10.1016/S1074-7613(01)00232-1
3. Meighan-Mantha RL, Hsu DK, Guo Y, Brown SA, Feng SY, Peifley KA, et al. The mitogen-inducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration. J Biol Chem (1999) 274:33166-76. doi:10.1074/jbc.274.46.33166
4. Feng SY, Guo Y, Factor VM, Thorgeirsson SS, Bell DW, Testa JR, et al. The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am J Pathol (2000) 156:1253-61. doi:10.1016/S0002-9440(10)64996-6
5. Bossen C, Ingold K, Tardivel A, Bodmer JL, Gaide O, Hertig S, et al. Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J Biol Chem (2006) 281:13964-71. doi:10.1074/jbc.M601553200
6. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov (2008) 7:411-25. doi:10.1038/nrd2488
7. Burkly LC, Michaelson JS, Zheng TS. TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses. Immunol Rev (2011) 244:99-114. doi:10.1111/j.1600-065X.2011.01054.x
8. Tran NL, McDonough WS, Savitch BA, Fortin SP, Winkles JA, Symons M, et al. Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and NF-kappaB and correlate with poor patient outcome. Cancer Res (2006) 66:9535-42. doi:10.1158/0008-5472.CAN-06-0418
9. Culp PA, Choi D, Zhang Y, Yin J, Seto P, Ybarra SE, et al. Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanisms. Clin Cancer Res (2010) 16:497-508. doi:10.1158/1078-0432.CCR-09-1929
10. Whitsett TG, Cheng E, Inge L, Asrani K, Jameson NM, Hostetter G, et al. Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion. Am J Pathol (2012) 181:111-20. doi:10.1016/j.ajpath.2012.03.026
11. Zhou H, Ekmekcioglu S, Marks JW, Mohamedali KA, Asrani K, Phillips KK, et al. The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment. J Invest Dermatol (2013) 133:1052-62. doi:10.1038/jid.2012.402
12. Chao DT, Su M, Tanlimco S, Sho M, Choi D, Fox M, et al. Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb. J Cancer Res Clin Oncol (2013) 139:315-25. doi:10.1007/s00432-012-1332-x
13. Li N, Hu WJ, Shi J, Xue J, Guo WX, Zhang Y, et al. Roles of fibroblast growth factor-inducible 14 in hepatocellular carcinoma. Asian Pac J Cancer Prev (2013) 14:3509-14. doi:10.7314/APJCP.2013.14.6.3509
14. Gu L, Dai L, Cao C, Zhu J, Ding C, Xu HB, et al. Functional expression of TWEAK and the receptor Fn14 in human malignant ovarian tumors: possible implication for ovarian tumor intervention. PLoS One (2013) 8:e57436. doi:10.1371/journal.pone.0057436
15. Brown SA, Ghosh A, Winkles JA. Full-length, membrane-anchored TWEAK can function as a juxtacrine signaling molecule and activate the NF-kappaB pathway. J Biol Chem (2010) 285:17432-41. doi:10.1074/jbc.M110.131979
16. Roos C, Wicovsky A, Muller N, Salzmann S, Rosenthal T, Kalthoff H, et al. Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappaB pathway. J Immunol (2010) 185:1593-605. doi:10.4049/jimmunol.0903555
17. Varfolomeev E, Goncharov T, Maecker H, Zobel K, Komuves LG, Deshayes K, et al. Cellular inhibitors of apoptosis are global regulators of NF-kappaB and MAPK activation by members of the TNF family of receptors. Sci Signal (2012) 5:ra22. doi:10.1126/scisignal.2001878
18. Watts GS, Tran NL, Berens ME, Bhattacharyya AK, Nelson MA, Montgomery EA, et al. Identification of Fn14/TWEAK receptor as a potential therapeutic target in esophageal adenocarcinoma. Int J Cancer (2007) 121:2132-9. doi:10.1002/ijc.22898
19. Willis AL, Tran NL, Chatigny JM, Charlton N, Vu H, Brown SA, et al. The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity. Mol Cancer Res (2008) 6:725-34. doi:10.1158/1541-7786.MCR-08-0005
20. Huang M, Narita S, Tsuchiya N, Ma Z, Numakura K, Obara T, et al. Overexpression of Fn14 promotes androgen-independent prostate cancer progression through MMP-9 and correlates with poor treatment outcome. Carcinogenesis (2011) 32:1589-96. doi:10.1093/carcin/bgr182
21. Brown SA, Cheng E, Williams MS, Winkles JA. TWEAK-independent Fn14 self-association and NF-kappaB activation is mediated by the C-terminal region of the Fn14 cytoplasmic domain. PLoS One (2013) 8:e65248. doi:10.1371/journal.pone.0065248
22. Tran NL, McDonough WS, Donohue PJ, Winkles JA, Berens TJ, Ross KR, et al. The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. Am J Pathol (2003) 162:1313-21. doi:10.1016/S0002-9440(10)63927-2
23. Maecker H, Varfolomeev E, Kischkel F, Lawrence D, LeBlanc H, Lee W, et al. TWEAK attenuates the transition from innate to adaptive immunity. Cell (2005) 123:931-44. doi:10.1016/j.cell.2005.09.022
24. Campbell S, Burkly LC, Gao HX, Berman JW, Su L, Browning B, et al. Proinflammatory effects of TWEAK/Fn14 interactions in glomerular mesangial cells. J Immunol (2006) 176:1889-98.
25. Jakubowski A, Ambrose C, Parr M, Lincecum JM, Wang MZ, Zheng TS, et al. TWEAK induces liver progenitor cell proliferation. J Clin Invest (2005) 115:2330-40. doi:10.1172/JCI23486
26. Burkly LC, Dohi T. The TWEAK/Fn14 pathway in tissue remodeling: for better or for worse. Adv Exp Med Biol (2011) 691:305-22. doi:10.1007/978-1-4419-6612-4_32
27. Dohi T, Burkly LC. The TWEAK/Fn14 pathway as an aggravating and perpetuating factor in inflammatory diseases: focus on inflammatory bowel diseases. J Leukoc Biol (2012) 92:265-79. doi:10.1189/jlb.0112042
28. Wajant H. The TWEAK-Fn14 system as a potential drug target. Br J Pharmacol (2013) 170:748-64. doi:10.1111/bph.12337
29. Medzhitov R. Origin and physiological roles of inflammation. Nature (2008) 454:428-35. doi:10.1038/nature07201
30. Gaestel M, Kotlyarov A, Kracht M. Targeting innate immunity protein kinase signalling in inflammation. Nat Rev Drug Discov (2009) 8:480-99. doi:10.1038/nrd2829
31. McCulloch CA, Downey GP, El-Gabalawy H. Signalling platforms that modulate the inflammatory response: new targets for drug development. Nat Rev Drug Discov (2006) 5:864-76. doi:10.1038/nrd2109
32. Shichita T, Sakaguchi R, Suzuki M, Yoshimura A. Post-ischemic inflammation in the brain. Front Immunol (2012) 3:132. doi:10.3389/fimmu.2012.00132
33. Mathers CD, Boerma T, Ma FD. Global and regional causes of death. Br Med Bull (2009) 92:7-32. doi:10.1093/bmb/ldp028
34. Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron (2010) 67:181-98. doi:10.1016/j.neuron.2010.07.002
35. Yepes M. TWEAK and the central nervous system. Mol Neurobiol (2007) 35:255-65. doi:10.1007/s12035-007-0024-z
36. Potrovita I, Zhang W, Burkly L, Hahm K, Lincecum J, Wang MZ, et al. Tumor necrosis factor-like weak inducer of apoptosis-induced neurodegeneration. J Neurosci (2004) 24:8237-44. doi:10.1523/JNEUROSCI.1089-04.2004
37. Yepes M, Brown SA, Moore EG, Smith EP, Lawrence DA, Winkles JA. A soluble Fn14-Fc decoy receptor reduces infarct volume in a murine model of cerebral ischemia. Am J Pathol (2005) 166:511-20. doi:10.1016/S0002-9440(10)62273-0
38. Haile WB, Echeverry R, Wu F, Guzman J, An J, Wu J, et al. Tumor necrosis factor-like weak inducer of apoptosis and fibroblast growth factor-inducible 14 mediate cerebral ischemia-induced poly(ADP-ribose) polymerase-1 activation and neuronal death. Neuroscience (2010) 171:1256-64. doi:10.1016/j.neuroscience.2010.10.029
39. Inta I, Frauenknecht K, Dorr H, Kohlhof P, Rabsilber T, Auffarth GU, et al. Induction of the cytokine TWEAK and its receptor Fn14 in ischemic stroke. J Neurol Sci (2008) 275:117-20. doi:10.1016/j.jns.2008.08.005
40. Zhang X, Winkles JA, Gongora MC, Polavarapu R, Michaelson JS, Hahm K, et al. TWEAK-Fn14 pathway inhibition protects the integrity of the neurovascular unit during cerebral ischemia. J Cereb Blood Flow Metab (2007) 27:534-44. doi:10.1038/sj.jcbfm.9600368
41. Polavarapu R, Gongora MC, Winkles JA, Yepes M. Tumor necrosis factor-like weak inducer of apoptosis increases the permeability of the neurovascular unit through NF-kappaB pathway activation. J Neurosci (2005) 25:10094-100. doi:10.1523/JNEUROSCI.3382-05.2005
42. Nylander A, Hafler DA. Multiple sclerosis. J Clin Invest (2012) 122:1180-8. doi:10.1172/JCI58649
43. Constantinescu CS, Farooqi N, O'Brien K, Gran B. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol (2011) 164:1079-106. doi:10.1111/j.1476-5381.2011.01302.x
44. Morris K, Yiannikas C. Treatment update in multiple sclerosis. Curr Allergy Asthma Rep (2012) 12:246-54. doi:10.1007/s11882-012-0256-5
45. Nazeri A, Heydarpour P, Sadaghiani S, Sahraian MA, Burkly LC, Bar-Or A. A further TWEAK to multiple sclerosis pathophysiology. Mol Neurobiol (2013). doi:10.1007/s12035-013-8490-y
46. Ransohoff RM. Animal models of multiple sclerosis: the good, the bad and the bottom line. Nat Neurosci (2012) 15:1074-7. doi:10.1038/nn.3168
47. Desplat-Jego S, Creidy R, Varriale S, Allaire N, Luo Y, Bernard D, et al. Anti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system and severity of experimental autoimmune encephalomyelitis. Clin Immunol (2005) 117:15-23. doi:10.1016/j.clim.2005.06.005
48. Mueller AM, Pedre X, Kleiter I, Hornberg M, Steinbrecher A, Giegerich G. Targeting fibroblast growth factor-inducible-14 signaling protects from chronic relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol (2005) 159:55-65. doi:10.1016/j.jneuroim.2004.10.001
49. Desplat-Jego S, Varriale S, Creidy R, Terra R, Bernard D, Khrestchatisky M, et al. TWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity. J Neuroimmunol (2002) 133:116-23. doi:10.1016/S0165-5728(02)00368-5
50. Iocca HA, Plant SR, Wang Y, Runkel L, O'Connor BP, Lundsmith ET, et al. TNF superfamily member TWEAK exacerbates inflammation and demyelination in the cuprizone-induced model. J Neuroimmunol (2008) 194:97-106. doi:10.1016/j.jneuroim.2007.12.003
51. Serafini B, Magliozzi R, Rosicarelli B, Reynolds R, Zheng TS, Aloisi F. Expression of TWEAK and its receptor Fn14 in the multiple sclerosis brain: implications for inflammatory tissue injury. J Neuropathol Exp Neurol (2008) 67:1137-48. doi:10.1097/NEN.0b013e31818dab90
52. Razmara M, Hilliard B, Ziarani AK, Murali R, Yellayi S, Ghazanfar M, et al. Fn14-TRAIL, a chimeric intercellular signal exchanger, attenuates experimental autoimmune encephalomyelitis. Am J Pathol (2009) 174:460-74. doi:10.2353/ajpath.2009.080462
53. Hilliard B, Wilmen A, Seidel C, Liu TS, Goke R, Chen Y. Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis. J Immunol (2001) 166:1314-9.
54. Prinz-Hadad H, Mizrachi T, Irony-Tur-Sinai M, Prigozhina TB, Aronin A, Brenner T, et al. Amelioration of autoimmune neuroinflammation by the fusion molecule Fn14-TRAIL. J Neuroinflamm (2013) 10:36. doi:10.1186/1742-2094-10-36
55. Schaeverbeke T, Truchetet Mé, Richez C. When and where does rheumatoid arthritis begin? Joint Bone Spine (2012) 79:550-4. doi:10.1016/j.jbspin.2012.09.004
56. Kurkó J, Besenyei T, Laki J, Glant TT, Mikecz K, Szekanecz Z. Genetics of rheumatoid arthritis-a comprehensive review. Clin Rev Allergy Immunol (2013) 45:170-9. doi:10.1007/s12016-012-8346-7
57. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (2012) 51(Suppl 5):v3-11. doi:10.1093/rheumatology/kes113
58. Trouw LA, Huizinga TW, Toes RE. Autoimmunity in rheumatoid arthritis: different antigens-common principles. Ann Rheum Dis (2013) 72(Suppl 2):ii132-6. doi:10.1136/annrheumdis-2012-202349
59. Rosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic therapy for autoimmune diseases: an update. BMC Med (2013) 11:88. doi:10.1186/1741-7015-11-88
60. van Kuijk AW, Wijbrandts CA, Vinkenoog M, Zheng TS, Reedquist KA, Tak PP. TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade. Ann Rheum Dis (2010) 69:301-4. doi:10.1136/ard.2008.090548
61. Park JS, Kwok SK, Lim MA, Oh HJ, Kim EK, Jhun JY, et al. TWEAK promotes osteoclastogenesis in rheumatoid arthritis. Am J Pathol (2013) 183:857-67. doi:10.1016/j.ajpath.2013.05.027
62. Dharmapatni AA, Smith MD, Crotti TN, Holding CA, Vincent C, Weedon HM, et al. TWEAK and Fn14 expression in the pathogenesis of joint inflammation and bone erosion in rheumatoid arthritis. Arthritis Res Ther (2011) 13:R51. doi:10.1186/ar3294
63. Park MC, Chung SJ, Park YB, Lee SK. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis. Scand J Rheumatol (2008) 37:173-8. doi:10.1080/03009740801898608
64. Park JS, Park MK, Lee SY, Oh HJ, Lim MA, Cho WT, et al. TWEAK promotes the production of interleukin-17 in rheumatoid arthritis. Cytokine (2012) 60:143-9. doi:10.1016/j.cyto.2012.06.285
65. Perper SJ, Browning B, Burkly LC, Weng S, Gao C, Giza K, et al. TWEAK is a novel arthritogenic mediator. J Immunol (2006) 177:2610-20.
66. Kamijo S, Nakajima A, Kamata K, Kurosawa H, Yagita H, Okumura K. Involvement of TWEAK/Fn14 interaction in the synovial inflammation of RA. Rheumatology (2008) 47:442-50. doi:10.1093/rheumatology/ken006
67. Kamata K, Kamijo S, Nakajima A, Koyanagi A, Kurosawa H, Yagita H, et al. Involvement of TNF-like weak inducer of apoptosis in the pathogenesis of collagen-induced arthritis. J Immunol (2006) 177:6433-9.
68. Wisniacki N, Amaravadi L, Galluppi GR, Zheng TS, Zhang R, Kong J, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis. Clin Ther (2013) 35:1137-49. doi:10.1016/j.clinthera.2013.06.008
69. Lateef A, Petri M. Unmet medical needs in systemic lupus erythematosus. Arthritis Res Ther (2012) 14(Suppl 4):S4. doi:10.1186/ar3919
70. Liu Z, Davidson A. Taming lupus-a new understanding of pathogenesis is leading to clinical advances. Nat Med (2012) 18:871-82. doi:10.1038/nm.2752
71. Michaelson JS, Wisniacki N, Burkly LC, Putterman C. Role of TWEAK in lupus nephritis: a bench-to-bedside review. J Autoimmun (2012) 39:130-42. doi:10.1016/j.jaut.2012.05.003
72. Kaplan MJ, Lewis EE, Shelden EA, Somers E, Pavlic R, McCune WJ, et al. The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells. J Immunol (2002) 169:6020-9.
73. Schwartz N, Rubinstein T, Burkly LC, Collins CE, Blanco I, Su L, et al. Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther (2009) 11:R143. doi:10.1186/ar2816
74. Liu ZC, Zhou QL, Li XZ, Yang JH, Ao X, Veeraragoo P, et al. Elevation of human tumor necrosis factor-like weak inducer of apoptosis in peripheral blood mononuclear cells is correlated with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Cytokine (2011) 53:295-300. doi:10.1016/j.cyto.2010.11.012
75. Wang C, Chen LL, Pan HF, Leng RX, Qin WZ, Ye DQ. Expression of human tumor necrosis factor-like weak inducer of apoptosis in patients with systemic lupus erythematosus. Clin Rheumatol (2012) 31:335-9. doi:10.1007/s10067-011-1865-4
76. Lu J, Kwan BC, Lai FM, Choi PC, Tam LS, Li EK, et al. Gene expression of TWEAK/Fn14 and IP-10/CXCR3 in glomerulus and tubulointerstitium of patients with lupus nephritis. Nephrology (2011) 16:426-32. doi:10.1111/j.1440-1797.2011.01449.x
77. El-Shehaby A, Darweesh H, El-Khatib M, Momtaz M, Marzouk S, El-Shaarawy N, et al. Correlations of urinary biomarkers, TNF-like weak inducer of apoptosis (TWEAK), osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), and IL-8 with lupus nephritis. J Clin Immunol (2011) 31:848-56. doi:10.1007/s10875-011-9555-1
78. Xuejing Z, Jiazhen T, Jun L, Xiangqing X, Shuguang Y, Fuyou L. Urinary TWEAK level as a marker of lupus nephritis activity in 46 cases. J Biomed Biotechnol (2012) 2012:359647. doi:10.1155/2012/359647
79. Zhao Z, Burkly LC, Campbell S, Schwartz N, Molano A, Choudhury A, et al. TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. J Immunol (2007) 179:7949-58.
80. Molano A, Lakhani P, Aran A, Burkly LC, Michaelson JS, Putterman C. TWEAK stimulation of kidney resident cells in the pathogenesis of graft versus host induced lupus nephritis. Immunol Lett (2009) 125:119-28. doi:10.1016/j.imlet.2009.06.010
81. Xia Y, Campbell SR, Broder A, Herlitz L, Abadi M, Wu P, et al. Inhibition of the TWEAK/Fn14 pathway attenuates renal disease in nephrotoxic serum nephritis. Clin Immunol (2012) 145:108-21. doi:10.1016/j.clim.2012.08.008
82. Wen J, Xia Y, Stock A, Michaelson JS, Burkly LC, Gulinello M, et al. Neuropsychiatric disease in murine lupus is dependent on the TWEAK/Fn14 pathway. J Autoimmun (2013) 43:44-54. doi:10.1016/j.jaut.2013.03.002
83. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin (2013) 63:11-30. doi:10.3322/caac.21166
84. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell (2011) 147:275-92. doi:10.1016/j.cell.2011.09.024
85. Sethi N, Kang Y. Unravelling the complexity of metastasis-molecular understanding and targeted therapies. Nat Rev Cancer (2011) 11:735-48. doi:10.1038/nrc3125
86. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer (2012) 12:237-51. doi:10.1038/nrc3237
87. Haber DA, Gray NS, Baselga J. The evolving war on cancer. Cell (2011) 145:19-24. doi:10.1016/j.cell.2011.03.026
88. Yin X, Luistro L, Zhong H, Smith M, Nevins T, Schostack K, et al. RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune response. Clin Cancer Res (2013) 19:5686-98. doi:10.1158/1078-0432.CCR-13-0405
89. Lassen U, Schellens JH, Siu LL, Jonker DJ, Sorensen M, Jarutat T, et al. A first-in-human phase 1 monotherapy study of RG7212 (R), a novel monoclonal antibody targeting TWEAK signaling in patients with advanced solid tumors. Eur J Cancer (2012) 48(Suppl 6):12. doi:10.1016/S0959-8049(12)71828-2
90. Aronin A, Amsili S, Prigozhina TB, Tzdaka K, Rachmilewitz J, Shani N, et al. Fn14-Trail effectively inhibits hepatocellular carcinoma growth. PLoS One (2013) 8:e77050. doi:10.1371/journal.pone.0077050
91. Michaelson JS, Amatucci A, Kelly R, Su L, Garber E, Day ES, et al. Development of an Fn14 agonistic antibody as an anti-tumor agent. MAbs (2011) 3:362-75. doi:10.4161/mabs.3.4.16090
92. Michaelson JS, Kelly R, Yang L, Zhang X, Wortham K, Joseph IB. The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models. Cancer Biol Ther (2012) 13:812-21. doi:10.4161/cbt.20564
93. Trebing J, Lang I, Chopra M, Salzmann S, Moshir M, Silence K, et al. A novel llama antibody targeting Fn14 exhibits anti-metastatic activity in vivo. MAbs (2014) 6. doi:10.4161/mabs.26709
94. Lam ET, Eckhardt SG, Messersmith W, Jimeno A, O'Bryant CL, Ramanathan RK, et al. A phase I study of enavatuzumab (PDL192, ABT-361), a first-in-class human monoclonal antibody targeting TWEAK (tumor necrosis factor-like inducer of apoptosis) receptor, in patients with advanced solid tumors. Mol Cancer Ther (2013) 10(Suppl 1):AbstractC18. doi:10.1158/1535-7163.TARG-11-C18
95. Zhou H, Marks JW, Hittelman WN, Yagita H, Cheung LH, Rosenblum MG, et al. Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells. Mol Cancer Ther (2011) 10:1276-88. doi:10.1158/1535-7163.MCT-11-0161
96. Zhou H, Hittelman WN, Yagita H, Cheung LH, Martin SS, Winkles JA, et al. Antitumor activity of a humanized, bivalent immunotoxin targeting Fn14-positive solid tumors. Cancer Res (2013) 73:4439-50. doi:10.1158/0008-5472.CAN-13-0187
97. Burkly LC, Michaelson JS, Hahm K, Jakubowski A, Zheng TS. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine (2007) 40:1-16. doi:10.1016/j.cyto.2007.09.007
98. Fortin SP, Ennis MJ, Savitch BA, Carpentieri D, McDonough WS, Winkles JA, et al. Tumor necrosis factor-like weak inducer of apoptosis stimulation of glioma cell survival is dependent on Akt2 function. Mol Cancer Res (2009) 7:1871-81. doi:10.1158/1541-7786.MCR-09-0194
99. Asrani K, Keri RA, Galisteo R, Brown SA, Morgan SJ, Ghosh A, et al. The HER2-and heregulin-beta1 (HRG)-inducible TNFR superfamily member Fn14 promotes HRG-driven breast cancer cell migration, invasion, and MMP9 expression. Mol Cancer Res (2013) 11:393-404. doi:10.1158/1541-7786.MCR-12-0542
100. Ho DH, Vu H, Brown SA, Donohue PJ, Hanscom HN, Winkles JA. Soluble tumor necrosis factor-like weak inducer of apoptosis overexpression in HEK293 cells promotes tumor growth and angiogenesis in athymic nude mice. Cancer Res (2004) 64:8968-72. doi:10.1158/0008-5472.CAN-04-1879
101. Michaelson JS, Burkly LC. Therapeutic targeting of TWEAK/Fnl4 in cancer: exploiting the intrinsic tumor cell killing capacity of the pathway. Results Probl Cell Differ (2009) 49:145-60. doi:10.1007/400_2008_18
102. Schneider P, Schwenzer R, Haas E, Muhlenbeck F, Schubert G, Scheurich P, et al. TWEAK can induce cell death via endogenous TNF and TNF receptor 1. Eur J Immunol (1999) 29:1785-92. doi:10.1002/(SICI)1521-4141(199906)29:06<1785::AID-IMMU1785>3.0.CO;2-U
103. Vince JE, Chau D, Callus B, Wong WW, Hawkins CJ, Schneider P, et al. TWEAK-Fn14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNF-alpha. J Cell Biol (2008) 182:171-84. doi:10.1083/jcb.200801010
104. Wicovsky A, Salzmann S, Roos C, Ehrenschwender M, Rosenthal T, Siegmund D, et al. TNF-like weak inducer of apoptosis inhibits proinflammatory TNF receptor-1 signaling. Cell Death Differ (2009) 16:1445-59. doi:10.1038/cdd.2009.80
105. Ikner A, Ashkenazi A. TWEAK induces apoptosis through a death-signaling complex comprising receptor-interacting protein 1 (RIP1), Fas-associated death domain (FADD), and caspase-8. J Biol Chem (2011) 286:21546-54. doi:10.1074/jbc.M110.203745
106. Chapman MS, Wu L, Amatucci A, Ho SN, Michaelson JS. TWEAK signals through JAK-STAT to induce tumor cell apoptosis. Cytokine (2013) 61:210-7. doi:10.1016/j.cyto.2012.09.020
107. Salzmann S, Seher A, Trebing J, Weisenberger D, Rosenthal A, Siegmund D, et al. Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity. J Biol Chem (2013) 288:13455-66. doi:10.1074/jbc.M112.435917
108. Kawakita T, Shiraki K, Yamanaka Y, Yamaguchi Y, Saitou Y, Enokimura N, et al. Functional expression of TWEAK in human hepatocellular carcinoma: possible implication in cell proliferation and tumor angiogenesis. Biochem Biophys Res Commun (2004) 318:726-33. doi:10.1016/j.bbrc.2004.04.084
109. Tran NL, McDonough WS, Savitch BA, Sawyer TF, Winkles JA, Berens ME. The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NF-kappaB pathway activation and BCL-XL/BCL-W expression. J Biol Chem (2005) 280:3483-92. doi:10.1074/jbc.M409906200
110. Donohue PJ, Richards CM, Brown SA, Hanscom HN, Buschman J, Thangada S, et al. TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler Thromb Vasc Biol (2003) 23:594-600. doi:10.1161/01.ATV.0000062883.93715.37
111. Bolognesi A, Polito L. Immunotoxins and other conjugates: pre-clinical studies. Mini-Rev Med Chem (2004) 4:563-83. doi:10.2174/1389557043403864
112. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin treatment of cancer. Annu Rev Med (2007) 58:221-37. doi:10.1146/annurev.med.58.070605.115320
113. Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E, Okumura K, et al. Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. J Immunol (2003) 170:341-8.
114. Nakayama M, Harada N, Okumura K, Yagita H. Characterization of murine TWEAK and its receptor (Fn14) by monoclonal antibodies. Biochem Biophys Res Commun (2003) 306:819-25. doi:10.1016/S0006-291X(03)01051-9
115. Stirpe F, Battelli MG. Ribosome-inactivating proteins: progress and problems. Cell Mol Life Sci (2006) 63:1850-66. doi:10.1007/s00018-006-6078-7
116. Kurschus FC, Jenne DE. Delivery and therapeutic potential of human granzyme B. Immunol Rev (2010) 235:159-71. doi:10.1111/j.0105-2896.2010.00894.x
117. Afonina IS, Cullen SP, Martin SJ. Cytotoxic and non-cytotoxic roles of the CTL/NK protease granzyme B. Immunol Rev (2010) 235:105-16. doi:10.1111/j.0105-2896.2010.00908.x
118. Frankel AE, Kreitman RJ, Sausville EA. Targeted toxins. Clin Cancer Res (2000) 6:326-34.
119. Borthakur G, Rosenblum MG, Talpaz M, Daver N, Ravandi F, Faderl S, et al. Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies. Haematologica (2013) 98:217-21. doi:10.3324/haematol.2012.071092
120. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer (2006) 6:714-27. doi:10.1038/nrc1913
121. Tiemann K, Rossi JJ. RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol Med (2009) 1:142-51. doi:10.1002/emmm.200900023
122. Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer (2011) 11:59-67. doi:10.1038/nrc2966
123. Burnett JC, Rossi JJ, Tiemann K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J (2011) 6:1130-46. doi:10.1002/biot.201100054
124. Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov (2010) 9:57-67. doi:10.1038/nrd3010
125. Zinzalla G, Thurston DE. Targeting protein-protein interactions for therapeutic intervention: a challenge for the future. Future Med Chem (2009) 1:65-93. doi:10.4155/fmc.09.12
126. He MM, Smith AS, Oslob JD, Flanagan WM, Braisted AC, Whitty A, et al. Small-molecule inhibition of TNF-alpha. Science (2005) 310:1022-5. doi:10.1126/science.1116304
127. Silvian LF, Friedman JE, Strauch K, Cachero TG, Day ES, Qian F, et al. Small molecule inhibition of the TNF family cytokine CD40 ligand through a subunit fracture mechanism. ACS Chem Biol (2011) 6:636-47. doi:10.1021/cb2000346
128. Carter PH, Scherle PA, Muckelbauer JK, Voss ME, Liu RQ, Thompson LA, et al. Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-alpha. Proc Natl Acad Sci U S A (2001) 98:11879-84. doi:10.1073/pnas.211178398
129. Benicchi T, Iozzi S, Svahn A, Axelsson H, Mori E, Bernocco S, et al. A homogeneous HTRF assay for the identification of inhibitors of the TWEAK-Fn14 protein interaction. J Biomol Screen (2012) 17:933-45. doi:10.1177/1087057112447873
130. He F, Dang W, Saito K, Watanabe S, Kobayashi N, Guntert P, et al. Solution structure of the cysteine-rich domain in Fn14, a member of the tumor necrosis factor receptor superfamily. Protein Sci (2009) 18:650-6. doi:10.1002/pro.49
131. Pellegrini M, Willen L, Perroud M, Krushinskie D, Strauch K, Cuervo H, et al. Structure of the extracellular domains of human and Xenopus Fn14: implications in the evolution of TWEAK and Fn14 interactions. FEBS J (2013) 280:1818-29. doi:10.1111/febs.12206
132. Lammens A, Baehner M, Kohnert U, Niewoehner J, von Proff L, Schraeml M, et al. Crystal structure of human TWEAK in complex with the Fab fragment of a neutralizing antibody reveals insights into receptor binding. PLoS One (2013) 8:e62697. doi:10.1371/journal.pone.0062697
133. Dhruv H, Loftus JC, Narang P, Petit JL, Fameree M, Burton J, et al. Structural basis and targeting of the interaction between fibroblast growth factor-inducible-14 and tumor necrosis factor-like weak inducer of apoptosis. J Biol Chem (2013) 288:32261-76. doi:10.1074/jbc.M113.493536
134. Brown SA, Hanscom HN, Vu H, Brew SA, Winkles JA. TWEAK binding to the Fn14 cysteine-rich domain depends on charged residues located in both the A1 and D2 modules. Biochem J (2006) 397:297-304. doi:10.1042/BJ20051362
135. Blanco-Colio LM, Martin-Ventura JL, Munoz-Garcia B, Moreno JA, Meilhac O, Ortiz A, et al. TWEAK and Fn14. New players in the pathogenesis of atherosclerosis. Front Biosci (2007) 12:3648-55. doi:10.2741/2341